Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/UMEC/VI single-inhaler triple therapy versus budesonide/formoterol plus tiotropium in COPD
NL-OMON46566Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of fluticasone, umeclidinium, vilanterol, budesonide, formoterol and 1 more in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Weighted mean change from baseline in FEV1 over 0-24 hours at Week 12. Started Sep 2018; status: active, not recruiting.
02
Drugs
fluticasoneumeclidiniumvilanterolbudesonideformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON46566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46566.